2022 / artigoscientificos

Dynamics of antibody response to CoronaVac vaccine

Abstract: CoronaVac was the first vaccine approved in Brazil for use in healthcare workers (HCWs). However, there is limited information about it, with little long-term evidence on post-vaccination antibody persistence. This study evaluated the antibody response to SARS-CoV-2 in 1237 HCWs after the first (1D), second dose (2D), and 6 months postvaccination (6mA2D) with CoronaVac. The seropositivity was 88% at 1D, increasing to 99.8% at 2D, but decreasing to 97.9% at 6mA2D, which was also observed at the analyzed antibody levels. Interestingly, the levels in females were higher than males, and we found a positive correlation with previous SARS-CoV-2 infection. Participants with comorbidities had lower levels suggesting the need to monitor for a potential booster dose. Our findings suggest that CoronaVac induced a robust antibody response that wanes significantly over time. Further longitudinal studies are needed to identify whether the antibodies will decline or plateau at a lower level.

jordana / noticias

Plataforma GISSA integrará o projeto Linha de Cuidado do câncer de colo de útero da mulher pernambucana

Os pesquisadores da Fiocruz Ceará e do Laboratório de Redes Inteligentes e Integradas em Saúde Digital (LARIISA), Odorico Monteiro e Ivana Barreto apresentaram uma nova ferramenta integrada ao GISSA, a Jornada da Mulher Pernambucana na Linha de Cuidado do Câncer de Colo de Útero (CCU), que poderá monitorar esse tipo de câncer desde a vacinação contra o vírus do HPV, ainda na adolescência, até o óbito da mulher, tudo isso a partir de dashboards, alertas, indicadores, mapas e relatórios. A apresentação aconteceu durante evento sobre a reestruturação da linha de cuidado do câncer de colo de útero, realizado em Pernambuco.